



Bal Pharma Limited

To,
The Manager-listing
National Stock Exchange of India Ltd
Mumbai.

10.02.2016

Dear Sir,

Sub : Out Come of the Board Meeting.

As already informed to the exchange, the Board of Directors of the Company has met today and *inter alia* has taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2015.

A copy of the approved financial results along with the limited review report issued by the statutory auditors of the Company is enclosed with this intimation.

Please take the same on record.

Thanking You

For Bal Pharma Ltd

Shailesh Siroya
Managing Director



Intertek




CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820



Sr. No.	Particulars	STANDALONE						Consolidated					
		Quarter ended		Nine Months ended		Year Ended		Quarter ended		Nine Months ended		Year Ended	
		31 Dec 15	30 Sep 15	31 Dec 14	Apr - Dec 15	Apr - Dec 14	31 Mar 15	31 Dec 15	30 Sep 15	Apr - Dec 15	Apr - Dec 15	31 Mar 15	31 Mar 15
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART I													
1	Income from Operations												
a)	Net Sales/Income from operations (Net of Excise Duty)	4,538.25	5,463.06	4,222.25	14,053.90	13,251.80	18,245.70	4,562.75	5,476.04	14,094.03	14,094.03	18,248.43	
b)	Other Operating Income	72.52	109.74	72.02	236.39	257.47	467.30	72.52	109.74	256.39	256.39	467.30	
	Total Income from Operations (net)	4,610.78	5,572.80	4,294.27	14,310.30	13,509.27	18,713.00	4,635.27	5,585.78	14,350.42	14,350.42	18,715.73	
2	Expenses												
a)	Cost of Materials Consumed	2,275.31	2,541.48	2,221.59	6,954.95	6,935.83	9,611.71	2,275.31	2,541.48	6,954.95	6,954.95	9,611.71	
b)	Purchase of Stock-in-Trade	202.69	122.33	116.09	465.17	406.48	207.89	207.89	133.58	482.73	482.73	627.69	
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(313.34)	463.41	(91.00)	(33.58)	(185.94)	(314.68)	(315.36)	463.24	(35.77)	(35.77)	(319.03)	
d)	Employee Cost	875.34	944.60	787.20	2,608.35	2,361.64	3,196.24	916.13	972.93	2,694.63	2,694.63	3,224.27	
e)	Depreciation and amortisation expenses	161.36	152.11	115.85	473.04	342.66	700.35	162.24	152.94	475.54	475.54	702.33	
f)	Other Expenditure	972.23	1,008.96	883.15	2,883.87	2,735.47	3,844.23	1,023.17	1,017.53	2,951.84	2,951.84	3,860.48	
	Total Expenses	4,171.58	5,233.09	4,032.88	13,351.79	12,596.14	17,660.74	4,269.37	5,281.70	13,523.91	13,523.91	17,707.45	
3	Profit from Operations before other income, finance costs and Exceptional items (1-2)	439.19	339.71	261.39	958.50	913.13	1,052.26	365.90	304.08	826.51	826.51	1,008.28	
4	Other Income	13.76	76.92	1.02	107.22	50.09	119.48	10.78	76.92	104.24	104.24	117.41	
5	Profit from ordinary activities before finance cost and Exceptional items (3+4)	452.95	416.63	262.41	1,065.72	963.22	1,171.74	376.68	381.00	930.75	930.75	1,125.69	
6	Finance Costs	170.99	137.43	158.23	438.44	307.13	651.62	171.03	137.45	438.51	438.51	651.64	
7	Profit from ordinary activities after finance costs but before Exceptional items (5-6)	281.96	279.20	104.18	627.28	456.09	520.12	205.65	243.55	492.24	492.24	474.05	
8	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	
9	Profit/Loss from ordinary activities Before Tax (7-8)	281.96	279.20	104.18	627.28	456.09	520.12	205.65	243.55	492.24	492.24	474.05	
10	Tax expense	80.49	70.98	25.76	169.33	109.48	117.84	90.22	61.25	169.33	169.33	118.74	
11	Net Profit from ordinary activities after Tax (9-10)	201.46	208.22	78.42	457.94	346.61	402.28	115.42	182.30	322.90	322.90	355.31	
12	Extra ordinary items (Net of tax)	-	-	-	-	-	-	-	-	-	-	-	
13	Net Profit / Loss for the period (11+12)	201.46	208.22	78.42	457.94	346.61	402.28	115.42	182.30	322.90	322.90	355.31	
14	Share of Profit/ (loss) of associates	-	-	-	-	-	-	(38.59)	(13.15)	(72.92)	(72.92)	(132.35)	
15	Minority Interest	-	-	-	-	-	-	(35.03)	(22.48)	(59.43)	(59.43)	(7.48)	
16	Net Profit / (Loss) after taxes and minority interest and share of Profit/ (loss) of associates (13+14+15)	201.46	208.22	78.42	457.94	346.61	402.28	189.05	217.93	455.26	455.26	495.14	
17	Paid-up Equity Share capital (face value of Rs 10 each)	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	4,070.99	-	-	-	-	4,031.50	
19	Earnings Per Share (before extraordinary items) (of Rs 10 each) (Not annualised)												
a)	Basic	1.57	1.62	0.81	3.44	2.71	3.14	1.52	0.21	1.73	1.73	2.83	
b)	Diluted	1.57	1.62	0.81	3.44	2.71	3.11	1.52	0.21	1.73	1.73	2.80	
19	Earnings Per Share (after extraordinary items) (of Rs 10 each) (Not annualised)												
a)	Basic	1.57	1.62	0.81	3.44	2.71	3.14	1.52	0.21	1.73	1.73	2.83	
b)	Diluted	1.57	1.62	0.81	3.44	2.71	3.11	1.52	0.21	1.73	1.73	2.80	

PART II

A) Particulars of Shareholding									
1) Public shareholding									
- Number of Shares	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570
- Percentage of shareholding	51.17	51.17	51.17	51.17	51.17	51.17	51.17	51.17	51.17
2) Promoters & Promoter group Shareholding									
a) Pledged / Encumbered									
- Number of Shares	-	-	-	-	-	-	-	-	-
- Percentage of shareholding	-	-	-	-	-	-	-	-	-
b) Non-encumbered									
- Number of Shares	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%
- Percentage of shareholding (as a % of total share capital of the company)	48.83	48.83	48.83	48.83	48.83	48.83	48.83	48.83	48.83


PART III

B) Investor Complaints			
- Pending at the beginning of the quarter	-		
- Received during the quarter	0		
- Disposed of during the quarter	0		
- Remaining unresolved at the end of the quarter	-		

Notes:

- 1 The above unaudited financial results as reviewed by the audit committee were approved by the Board of Directors at its meeting held on 10.02.2016
- 2 Statutory auditors have conducted limited review on the unaudited financial results for the quarter ended 31.12.2015
- 3 Previous year figures were regrouped/rearranged to conform to the classification of current year.
- 4 As the company deals with single product i.e pharmaceuticals, segment wise figures are not furnished.

Bangalore
10 Feb 16



By order of the Board of Directors
For Bal Pharma limited
Shan
Shalish Siroya
Managing Director

Shan